A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of

Clinical Trial Description

A randomized, open-label, parallel design study in healthy participants to assess the effects of itraconazole and rifampin on the single-dose pharmacokinetics of BMS-986205. Safety and tolerability data to be collected and assessed as well. ;

Study Design

Related Conditions & MeSH terms

Malignancies Multiple

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02961101` - Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies	Phase 1/Phase 2
Active, not recruiting	`NCT03678883` - 9-ING-41 in Patients With Advanced Cancers	Phase 2
Recruiting	`NCT04151342` - CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
Completed	`NCT04953065` - Coronavirus Disease 2019 (COVID-19) Vaccination in Cancer Patients

See also

Status

Clinical Trial

Phase

Recruiting

NCT02961101 - Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Phase 1/Phase 2

Active, not recruiting

NCT03678883 - 9-ING-41 in Patients With Advanced Cancers

Phase 2

Recruiting

NCT04151342 - CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Completed

NCT04953065 - Coronavirus Disease 2019 (COVID-19) Vaccination in Cancer Patients

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03346837
Study type	Interventional
Source	Bristol-Myers Squibb
Contact
Status	Completed
Phase	Phase 1
Start date	November 22, 2017
Completion date	December 20, 2017

A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms